Brain-Training Firm, FTC Settle

San Francisco-based Lumos Labs, creator of the brain-training program Lumosity, will pay $2 million to settle deceptive-advertising charges raised by the US Federal Trade Commission.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PEXELSThe company behind the popular brain-training program Lumosity will pay the US Federal Trade Commission (FTC) $2 million in a settlement related to deceptive advertising charges, the agency announced yesterday (January 5). As part of the settlement, San Francisco-based Lumos Labs is to notify Lumosity customers of the FTC action and provide instructions to cancel auto-renewal billing. (The program is available for purchase through monthly or lifetime subscriptions.)

“Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” Jessica Rich, director of the FTC’s Bureau of Consumer Protection, said in the statement. “But Lumosity simply did not have the science to back up its ads.” (See “Opinion: Can the Brain Be Trained?”)

In a statement sent to reporters (via Reuters), Lumos Labs said the FTC charges were tied to “marketing language that has been discontinued.” STAT News reported that the company said its focus “will not change.”

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tracy Vence

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo